Estimating the potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs

Alvin X. Han (), Emma Hannay, Sergio Carmona, Bill Rodriguez, Brooke E. Nichols and Colin A. Russell ()
Additional contact information
Alvin X. Han: Amsterdam University Medical Center, University of Amsterdam
Emma Hannay: Foundation for Innovative New Diagnostics (FIND)
Sergio Carmona: Foundation for Innovative New Diagnostics (FIND)
Bill Rodriguez: Foundation for Innovative New Diagnostics (FIND)
Brooke E. Nichols: Amsterdam University Medical Center, University of Amsterdam
Colin A. Russell: Amsterdam University Medical Center, University of Amsterdam

Nature Communications, 2023, vol. 14, issue 1, 1-13

Abstract: Abstract Oral antivirals have the potential to reduce the public health burden of COVID-19. However, now that we have exited the emergency-phase of the COVID-19 pandemic, declining SARS-CoV-2 clinical testing rates (average testing rates = $$\ll$$ ≪ 10 tests/100,000 people/day in low-and-middle income countries;

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-43769-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-43769-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-43769-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().